[Early clinical results with mycophenolate mofetil in immunosuppressive therapy of ocular pemphigoid].
BACKGROUND
Ocular cicatrical pemphigoid can lead to severe structural damage or loss of vision at worst. Longterm therapy with dapsone or systemic immunosuppressive therapy, e.g. with cyclophosphamide is often inevitable. Immunosuppression may cause severe side effects in some patients.


METHODS
Data are presented on 5 patients with ocular cicatrical pemphigoid who were treated with mycophenolate mofetil 2 g daily. Criterion of effectiveness was the clinical course of the condition defined as nonprogression of the morphologic alterations. Patients were initially examined and interviewed routinely every four weeks for the first four months, then every eight weeks. Patients were asked about side effects and underwent monthly blood checks.


RESULTS
All patients were followed for at least 12 months. Mycophenolate mofetil proved to be effective with respect to the clinical course in 9 out of 10 eyes. All patients showed regression of inflammatory conjunctival alteration and improvement of their complaints. In one eye the inflammatory process restarted after surgery due to excessive symblephara had been performed. Gastrointestinal side effects were reported in the initial phase, e.g. lack of appetite, nausea and mild diarrhoea.


CONCLUSIONS
Mycophenolate mofetil proved to be an effective immunosuppressant for the treatment of ocular cicatrical pemphigoid. Namely side effects were less severe and frequent compared to those known from other currently administered immunosuppressants. Longterm results and larger case numbers are needed to sustain these early results.
Zurdel
J
J
Augenklinik, Universitäts-Krankenhaus Eppendorf, Martinistr. 52, 20246 Hamburg. zurdel@uke.uni-hamburg.de
Aboalchamat
B
B
Zierhut
M
M
Stübiger
N
N
Bialasiewicz
A
A
Engelmann
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007638:Keratoconjunctivitis Sicca / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D008297:Male; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D010390:Pemphigoid, Benign Mucous Membrane / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014792:Visual Acuity
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid